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O R I G I N A L  A R T I C L E
Uncorrected refractive error is the leading cause of vi-sual impairment throughout the world.1-3 Laser cor-neal refractive surgery is an effective alternative to 
the correction of refractive errors with spectacles or contact 
lenses, especially for myopia. During the past 25 years, sev-
eral surgical techniques have been developed that change 
refraction by reshaping the cornea through excimer laser 
photoablative removal of corneal tissue. Photorefractive ker-
atectomy (PRK), which involves mechanically debriding the 
central corneal epithelium and then photoablating the under-
ABSTRACT
PURPOSE: To systematically compare the efficacy, pre-
dictability, safety, postoperative haze, pain scores, and 
epithelial healing time of four corneal surface ablation 
procedures.
METHODS: PubMed, Embase, Cochrane Library, and 
the U.S. trial registry were searched up to June 2018. 
Randomized controlled trials were selected. Efficacy 
(uncorrected distance visual acuity of 20/20 or bet-
ter), predictability (refractive spherical equivalent within 
±0.50 diopters [D] of the target), and safety (loss of 
two or more lines of spectacle corrected distance visual 
acuity) were set as primary outcome measures. Haze, 
pain scores, and epithelial healing time were set as sec-
ondary outcome measures.
RESULTS: Eighteen studies involving 1,423 eyes were 
included. According to the Grading of Recommendations 
Assessment, Development, and Evaluation, the quality of 
outcomes were moderate to high (70.6%). There were 
no differences in efficacy, predictability, safety, haze, day 
1 pain, and epithelial healing time between treatments. 
Epithelial laser in situ keratomileusis (epi-LASIK) had sta-
tistically significantly higher pain scores on day 3 com-
pared to photorefractive keratectomy (PRK) (weighted 
mean differences [WMD] = 2.2, 95% credible intervals 
[CrI] = 0.19 to 4.01) and transepithelial PRK (T-PRK) 
(WMD = 2.7, 95% CrI = 0.51 to 4.84). The surface 
under the cumulative ranking curve ranking results (best 
to worst) showed laser epithelial keratomileusis (LASEK) 
ranked highest for efficacy, predictability, safety, and day 
1 pain scores. Epi-LASIK ranked best for grade 1 haze 
scores. T-PRK ranked best for haze of 0.5 or higher, haze 
scores day 3 pain scores, and epithelial healing time.
CONCLUSIONS: Surface laser refractive surgeries are 
comparable in terms of efficacy, predictability, safety, 
and postoperative haze except for day 3 pain scores, 
with epi-LASIK being more painful compared to PRK and 
T-PRK.
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lying stromal surface, was the first of these techniques 
described.4-6 However, because it is a surface ablation 
procedure, PRK has limitations such as postoperative 
pain, delayed epithelial healing, and anterior stro-
mal haze development.7,8 As such, PRK declined in 
popularity with the introduction and development of 
intrastromal ablative techniques such as laser in situ 
keratomileusis (LASIK).9-11 However, surface ablation 
procedures such as PRK retain certain advantages over 
LASIK, such as inflicting less corneal biomechanical 
insult and avoiding both intraoperative and late flap-
related complications.12-14 Therefore, during the past 
two decades, other surface ablation procedures have 
been developed to try to overcome some of the limi-
tations of PRK while retaining its advantages. These 
procedures include transepithelial photorefractive 
keratectomy (T-PRK), laser epithelial keratomileusis 
(LASEK),15 and epithelial LASIK (epi-LASIK).16,17 
A fundamental difference between the various surface 
ablative techniques is the method of epithelial removal. 
Alcohol or mechanical debridement has been advo-
cated for the preservation of the epithelium as a flap, as 
in LASEK and epi-LASIK, respectively.18 This flap can 
then be placed over the ablated stromal surface to reduce 
postoperative pain and speed epithelial healing time. Al-
ternatively, epithelial removal can be undertaken by the 
laser itself as in T-PRK. This technique has several per-
ceived advantages, including no instrument contact with 
the cornea, reduced intervention time, and the potential 
to minimize the size of the epithelial defect required for 
stromal ablation, as well as the avoidance of alcohol and 
potential toxicity as in LASEK.19 Although these new ap-
proaches to surface laser ablation offer apparent theoreti-
cal improvements over traditional PRK, they each have 
different advantages and disadvantages. What is current-
ly lacking is a comprehensive evidence-based approach 
to determine the relative merits of each of these proce-
dures over each other and PRK. 
Although several conventional pairwise meta-
analyses of the four surface refractive ablation pro-
cedures (PRK, LASEK, epi-LASIK, and T-PRK) have 
been published,20-23 these publications share several 
limitations. First, they are unable to provide clear hi-
erarchies for these four available treatments due to a 
lack of head-to-head comparisons. Second, some pre-
vious analyses included non-randomized controlled 
trials that might influence the quality of the evidence. 
However, a network meta-analysis can combine direct 
evidence from individual trials and indirect evidence 
gleaned using statistical techniques across trials, en-
abling simultaneous “all-way” comparisons of mul-
tiple interventions.24 This technique is therefore par-
ticularly suitable to address questions relating to the 
relative safety and benefits of different treatment mo-
dalities for a single condition. We therefore performed 
this network meta-analysis of available randomized 
controlled trials (RCTs) to systematically compare 
the efficacy, predictability, safety, postoperative haze, 
pain scores, and epithelial healing time of the four ma-
jor surface ablative procedures described above and to 
provide evidence-based rankings of these treatments.
METHODS
This systematic review complies with the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) network meta-analysis extension 
statement.25
OutcOme measurements 
Efficacy (uncorrected distance visual acuity 
[UDVA] of 20/20 or better), predictability (refractive 
spherical equivalent [SE] within ±0.50 diopters [D] 
of the target), and safety (loss of two or more lines 
of spectacle corrected distance visual acuity [CDVA]) 
were set as primary outcome measures. Haze, pain 
scores, and epithelial healing time were set as sec-
ondary outcome measures. Pain data were assessed 
using a 10-point scale at days 1 and 3 postoperatively. 
When data at day 3 were not available, the outcome at 
the follow-up time point closest to day 3, such as day 
2 or day 4, was used. The results of efficacy, predict-
ability, safety, and haze were analyzed at 6 months 
postoperatively. When data at 6 months were not 
available, the outcome at the follow-up time point 
closest to 6 months was used.
eligibility criteria
Trials were included if they met the following cri-
teria: (1) treated population: patients with myopia; (2) 
interventions: PRK, T-PRK, LASEK, or epi-LASIK; (3) 
comparisons: two or more laser corneal surface abla-
tion techniques (as listed above); (4) at least one of the 
following outcomes: efficacy, safety, predictability, 
postoperative haze, pain, and epithelial healing time; 
and (5) study design: RCTs. We excluded trials if they 
contained only one of the surface ablation techniques, 
did not use randomization for treatment allocation, 
used mitomycin C (MMC) during surgery, or if partici-
pants were followed up for less than 3 months after 
surgery. MMC was not included due to the controver-
sial nature of the use of this drug.
search methOds
A systematic literature review was conducted us-
ing PubMed, Embase, The Cochrane Library, and the 
U.S. trial registry (www.ClinicalTrial.gov) for RCTs 
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published up to June 2018 without language restric-
tions. The full search strategies are shown in Table A 
(available in the online version of this article). We also 
manually examined the reference lists of clinical tri-
als, related meta-analyses, and systematic reviews to 
identify relevant studies.
study selectiOn
Screening was performed by two independent in-
vestigators (YH, BS). They retrieved the full-text ar-
ticles that appeared relevant after reviewing the titles 
and abstracts and independently assessed them for 
final eligibility. Any discrepancies were resolved by 
focused discussion or consultation with an additional 
investigator (RT).
data extractiOn and risk Of bias assessment
Two investigators independently extracted informa-
tion into an electronic database, including the partici-
pant and intervention characteristics, outcomes, and 
quantitative results for treatment effects. For data that 
were missing or could not be directly obtained, we 
contacted the authors of trial reports or used GetData 
GraphDigitizer 2.24 (http://getdata-graph-digitizer.com) 
to read data from figures. 
To appraise the study quality, the Cochrane Collab-
oration risk-of-bias method was used.26 In this method, 
we graded all reports at low, high, or unclear risk of 
bias for each of the following items: random sequence 
generation and allocation concealment (both items 
relate to selection bias), masking of participants and 
personnel (detection bias), incomplete outcome data 
(attrition bias), selective reporting (reporting bias), and 
other biases. Two investigators also independently 
assessed the quality of the body of evidence for out-
comes within the network meta-analysis according to 
the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) method as very low, 
low, moderate, or high.27 The GRADE considered the 
following domains: study limitations, indirectness, in-
consistency, imprecision of effect estimates, and risk 
of reporting bias.
data analysis
We first conducted traditional pairwise meta-analyses 
for direct comparisons using random-effects models. For 
binary outcomes, relative effect sizes were calculated as 
odds ratios (ORs) with 95% confidence intervals (CIs). 
For continuous outcomes, relative effect sizes were cal-
culated as weighted mean differences (WMDs) with 95% 
CI. For positive outcomes (ie, efficacy and predictability, 
where a greater value indicates a better result), an OR of 
greater than 1 or WMD of greater than 0 corresponded 
to beneficial treatment effects of the first treatment com-
pared with the second treatment. When the outcomes 
were negative (ie, safety, haze, pain, or epithelial healing 
time, where a greater value indicates a worse result), an 
OR of less than 1 or WMD of less than 0 corresponded 
to beneficial treatment effects of the first treatment com-
pared with the second treatment. We used visual inspec-
tion of the forest plots and the I2 statistic28 (values of 50% 
or more indicated substantial heterogeneity) to investi-
gate the possibility of statistical heterogeneity. We used 
STATA software (version 12.0; StataCorp LP, College 
Station, TX) for statistical analyses. 
To incorporate indirect comparisons, we performed 
Bayesian random-effects network meta-analyses using 
Markov chain Monte Carlo methods in GeMTC GUI 
0.14.329 to estimate pooled ORs and WMD with 95% 
credible intervals (CrI). We used four parallel chains 
and obtained 50,000 samples after a 20,000-sample 
burn-in in each chain. To check convergence, we used 
the Gelman and Rubin diagnostic30 and trace plots. 
We ranked treatments based on the analysis of rank-
ing probabilities and the surface under the cumula-
tive ranking curve (SUCRA).31 The SUCRA values, 
expressed as a percentage, showed the relative prob-
ability of an intervention being the best option. In-
consistency between direct and indirect evidence was 
assessed by a “node-splitting” approach.32 When high 
heterogeneity or inconsistency was found, a “leave-
one-out procedure” in which each trial is left out, one 
at a time, was done for further sensitivity analyses. 
Funnel plots were used to evaluate publication bias in 
the results between small and large studies.33
RESULTS
study selectiOn
Figure A (available in the online version of this ar-
ticle) shows the detailed steps of the study selection 
process. The literature search yielded 608 potentially 
relevant studies (the detailed search strategy is shown 
in Table A). Of these, 36 potentially eligible studies 
were retrieved from the electronic databases and 5 ad-
ditional studies were located from the references of 
selected studies, making a total of 41. After excluding 
23 studies on the basis of the predefined inclusion cri-
teria, 18 studies were included in the network meta-
analysis.
study characteristics and netwOrk geOmetry
A summary of all eligible studies is shown in Table 
B (available in the online version of this article). In-
cluded trials were published between 2001 and 2014. 
A total of 1,399 eyes that underwent one of the four 
different interventions were evaluated: 606 eyes in the 
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PRK group, 616 eyes in the LASEK group, 105 eyes in 
the epi-LASIK group, and 72 eyes in the T-PRK group 
(Figure B, available in the online version of this arti-
cle). All trials had two treatment arms, with the excep-
tion of O’Doherty et al.,34 which had three treatment 
arms. Of the included 18 trials, 5 (27.8%) recruited 
participants from Europe, 7 (38.9%) recruited partici-
pants from Asia, 4 (22.2%) recruited participants from 
North America, and 2 (11.1%) recruited participants 
from Brazil. 
Quality Of the evidence
The quality of the studies included in the network 
meta-analysis is shown in Table C-1 (Quality of the In-
cluded Trials) and Table C-2 (Analysis by Synthesis) 
(available in the online version of this article). In rela-
tion to the complete outcome data, almost 25% of trials 
were rated as “high risk of bias” (4 trials, 22.2%), but 
most were rated as “low risk of bias” (11 trials, 61.1%). 
Those rated as “unclear risk of bias” reported alloca-
tion concealment and masking of outcome assess-
ment (14 and 12 trials, respectively). The results of the 
GRADE are shown in Table C-3 (available in the online 
version of this article). Across the outcomes of the net-
work meta-analysis, we found 8 comparisons (15.7% 
of all comparisons) of high quality, 28 (54.9%) of mod-
erate quality, and 15 (29.4%) of low quality. The com-
parisons were all assessed as moderate-high quality for 
efficacy, predictability, safety, and pain scores on day 
3, and low-moderate for haze, pain scores on day 1, 
and epithelial healing time. For most of the outcomes, 
the main issues that reduced confidence in estimates 
were risk of bias and imprecision.
results Of meta-analysis
Direct Comparisons. Table 1 shows the results 
of efficacy, predictability, and safety based on direct 
comparisons. Ten articles reported the percentage of 
eyes with UDVA of 20/20 or better postoperatively 
(defined as efficacy). The results show that there was 
no statistically significant difference between the four 
major types of corneal surface ablation laser refrac-
tive surgery and high heterogeneity for all compari-
sons. Predictability was measured by the proportion 
of eyes where the postoperative refractive error was 
within ±0.50 D of the target refraction. We found that 8 
studies had sufficient data for this analysis. Statistical 
analyses of these data showed no statistically signifi-
cant effect of the type of corneal surface ablation laser 
refractive surgery. The proportion of eyes with a loss 
of two or more lines of CDVA was used as a measure of 
safety. This parameter was reported in 6 studies. The 
results show that there was no statistically significant 
difference between the types of corneal surface abla-
tion laser refractive surgery and high heterogeneity for 
all comparisons (I2 < 50%).
Tables 2-3 show the results of postoperative haze, 
pain scores, and epithelial healing time based on direct 
comparisons. Six trials reported haze scores. We found 
one statistically significant difference between LASEK 
and PRK (WMD = -0.19, 95% CI = -0.37 to -0.01), where-
as high heterogeneity was observed between LASEK 
and PRK (I2 = 88.9%) (forest plots in Table D, available 
in the online version of this article). We also analyzed 
the data at two different grades (grade 0.5 or higher and 
grade 1.0 or higher) in 7 trials; no statistically significant 
difference between the types of corneal surface ablation 
laser refractive surgery was found and high heterogene-
ity was found for both grades (I2 < 50%).
Six studies reported postoperative pain scores. We 
analyzed the postoperative pain scores at days 1 and 3. 
Statistically significant differences were found between 
PRK and T-PRK at day 1 (WMD = 1.24, 95% CI = 1.00 to 
1.48), LASEK and T-PRK at day 1 (WMD = -1.23, 95% 
CI = -2.10 to -0.36), PRK and epi-LASIK at day 3 (WMD 
= -2.16, 95% CI = -3.55 to -0.77), and PRK and T-PRK at 
day 3 (WMD = 0.48, 95% CI = 0.23 to 0.73). There was 
no high heterogeneity for all comparisons (I2 < 50%).
Twelve studies reported epithelial healing time. A 
statistically significant difference was found between 
PRK and T-PRK (WMD = 1.57, 95% CI = 1.33 to 1.75). 
We also found high heterogeneity between PRK and 
epi-LASIK (I2 = 91.4%), PRK and LASEK (I2 = 97.1%), 
and LASEK and epi-LASIK (I2 = 76.6%) (forest plots 
are shown in Table D).
Combination of Direct and Indirect Comparisons. 
Figure C (available in the online version of this article) 
shows the results of efficacy, predictability, and safety 
based on Bayesian network meta-analyses that combine 
direct and indirect comparisons. The ranking probabili-
ties for all procedures are presented in Table E (avail-
able in the online version of this article), along with the 
ranking probabilities of other results. For the primary 
outcomes, there were no statistically significant differ-
ences in any comparison in terms of efficacy, safety, and 
predictability (P > .05). For the ranking results, LASEK 
came first in efficacy, predictability, and safety on the 
SUCRA values (Figure 1). The results for postopera-
tive haze based on Bayesian network meta-analyses are 
shown in Figure D (available in the online version of 
this article). There was no statistically significant dif-
ference between any of the studied techniques (P > .05). 
For haze scores, epi-LASIK had the least haze as per 
the SUCRA values. T-PRK ranked first in haze scores 
at grade 0.5 or higher, whereas epi-LASIK ranked first 
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Figure 1. Ranking plot of the surface ablation surgery network based 
on surface under the cumulative ranking curve (SUCRA) values for 
(A) postoperative efficacy (uncorrected distance visual acuity [UDVA] 
of 20/20 or better), (B) predictability (refractive spherical equivalent 
[SE] within ±0.50 diopters [D] of the target refraction), and (C) safety 
(losing two or more lines of corrected distance visual acuity [CDVA]). 
epi-LASIK = epithelial laser in situ keratomileusis; LASEK = laser 





Figure 2. Ranking plot of procedures based on surface under the cumu-
lative ranking curve (SUCRA) values for (A) postoperative haze scores, 
(B) haze grade of 0.5 or higher, and (C) haze grade of 1.0. epi-LASIK 
= epithelial laser in situ keratomileusis; LASEK = laser epithelial ker-






The results for pain scores and epithelial healing 
time can be seen in Figure E (available in the online 
version of this article). As shown, statistically signifi-
cant differences only exist when epi-LASIK was com-
pared with PRK (WMD = 2.17, 95% CrI = 0.19 to 4.01) 
and T-PRK (WMD = 2.69, 95% CrI = 0.51 to 4.84) in 
terms of pain scores on day 3. LASEK ranked high-
est for pain on day 1 and T-PRK had the least pain on 
day 3. T-PRK ranked first in terms of epithelial healing 
time (Figure 3).
Inconsistency. Node-splitting analysis between 
LASEK, PRK, and T-PRK for closed-loop comparisons 
in terms of pain score on day 1 shows significant in-
consistency (P = .05). However, for other results com-
parisons between direct and indirect estimates did not 
suggest significant inconsistency between direct and 
indirect evidence (Table F, available in the online ver-
sion of this article, P value varying from .22 to .99).  
Sensitivity Analysis. For further sensitivity analy-
ses, we undertook a “leave-one-out procedure” in 
which each trial is left out, one at a time (full process 
and data shown in Table G, available in the online ver-
sion of this article). This process produced no signifi-
cant change in the results. 
For the postoperative haze scores in direct compari-
son of LASEK and PRK (WMD = -0.19, 95% CrI = -0.37 
to -0.01, I2 = 88.9%), there was a statistically signifi-
cant difference. When removing any single article, I2 
values were all still greater than 65% and the result 
turned to no statistically significant difference except 
when removing Ghanem et al.35 (WMD = -0.25, 95% 
CrI = -0.44 to -0.07, I2 = 84.8%). For pain score on day 
1, no statistically significant difference between any of 
the studied techniques was found when removing any 
study.
For epithelial healing time, high heterogeneity was 
found. This heterogeneity remained even after remov-
ing the two largest contributors, which prevented any 
meaningful sensitivity analysis for this outcome. This 
variability indicates the need for cautious interpreta-
tion of our data on epithelial healing time.
Publication Bias. Comparison-adjusted funnel plots 
for each outcome including all primary outcomes and 
secondary outcomes are provided in Table H (avail-
able in the online version of this article). Most of these 
plots show that the included studies lie symmetrically 
around the 0 line (vertical line); we did not find evi-
dence of a small-study effect or significant publication 
bias in the network. 
DISCUSSION
This study provides an in-depth statistical com-
parison of the four major excimer laser corneal surface 
ablation refractive procedures: PRK, T-PRK, LASEK, 
and epi-LASIK, for correcting myopia, combining data 
from 18 trials and 1,399 eyes. In addition to efficacy, 
Figure 3. Ranking plot of procedures based on surface under the cumulative 
ranking curve (SUCRA) values for postoperative pain scores on (A) day 1 and 
(B) day 3 and (C) epithelial healing time. epi-LASIK = epithelial laser in situ 
keratomileusis; LASEK = laser epithelial keratomileusis; PRK = photorefrac-
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predictability, and safety, it also considers a wide 
range of clinically relevant outcomes including post-
operative pain, haze, and epithelial healing time. The 
variety of available surface ablation techniques and the 
lack of large definitive trials with multiple treatment 
arms make a network meta-analysis particularly useful 
in this field. According to GRADE, the quality of out-
comes within this network meta-analysis was mostly 
evaluated as moderate or high (70.6%), which indicat-
ed an acceptable level of evidence.
The main conclusion of our network meta-analysis 
is the confirmation36 that all surface laser refractive 
technologies included in this analysis have excellent 
efficacy, predictability, and safety, at least in the short 
term (6 months after surgery). For many of the out-
comes analyzed, no statistically significant differences 
were found (ie, in relation to efficacy, predictability, 
safety, postoperative haze, day 1 pain score, and epi-
thelial healing time) (Tables 1-3). However, in terms of 
pain score on day 3, epi-LASIK was significantly more 
painful compared to PRK and T-PRK (Table 3). 
In addition to determining the statistical differences 
of specific outcomes between procedures, our analy-
sis (using SUCRA) provides a numerical ranking of all 
procedures for each outcome. SUCRA values show the 
relative probability of an intervention being the best 
option, providing an estimate of the relative domi-
nance of the treatment in the absence of significant dif-
ferences in statistical analysis. LASEK demonstrates 
relative advantages in three visual outcomes (efficacy, 
predictability, and safety) compared with the other 
techniques assessed, but results in greater postopera-
tive corneal haze. Epi-LASIK demonstrates better haze 
scores while performing less well in relation to post-
operative comfort (pain score and epithelial healing 
time). T-PRK tops the rankings in relation to postop-
erative haze grade 0.5 or higher, pain scores, and epi-
thelial healing time, whereas PRK fails to achieve top 
ranking in any of the studied outcomes. 
Efficacy, predictability, and safety are the most im-
portant outcomes in evaluations of corneal refractive 
surgery.37,38 There are several trials and meta-analyses 
that compare the direct evidence for these three out-
comes between different surface laser procedures. In 
2010, Zhao et al.20 performed a meta-analysis to exam-
ine possible differences in efficacy and predictability 
between LASEK and PRK. They indicated that LASEK 
had no significant benefits over PRK in terms of effi-
cacy (OR = 0.86, 95% CI = 0.61 to 1.20) or predict-
ability (OR = 0.90, 95% CI = 0.63 to 1.29). Wu et al.21 
compared epi-LASIK and PRK in relation to efficacy 
and predictability, reporting no statistically significant 
differences in either efficacy (relative risk = 1.43, 95% 
CI = 0.85 to 2.40) or predictability (relative risk = 1.03, 
95% CI = 0.92 to 1.16). These findings are similar to 
our results, although we also found no statistically sig-
nificant difference in safety when PRK was compared 
with either epi-LASIK or LASEK. However, we found 
that LASEK demonstrated relative advantages in these 
three outcomes in terms of ranking and that PRK ranks 
lowest for both predictability and safety. 
Postoperative haze formation is an important factor 
that may directly influence the efficacy, safety, and vi-
sual quality of corneal refractive surgery. Zhao et al.20 
contrasted LASEK and PRK in terms of corneal haze, 
reporting that no statistically significant difference was 
observed between the LASEK-treated groups and PRK-
treated groups at 6 months after surgery (WMD = 0.14, 
95% CI = -0.02 to 0.30), which was similar to our results 
(Table 2). We found that epi-LASIK and T-PRK per-
formed best on SUCRA ranking in terms of haze. These 
findings may be associated with the release of trans-
forming growth factor (TGF)-1. The researchers found 
TGF-1 is released into the tear film by the lacrimal gland 
after corneal epithelial injury and TGF-1 levels corre-
lated positively with the degree of haze, whereas tear 
fluid TGF-1 levels were less following epi-LASIK than 
after LASEK.39,40 As previously mentioned, high het-
erogeneity was found in direct comparison of LASEK 
and PRK, and we could not identify a particular study 
as the source of high heterogeneity through sensitivity 
analysis. We propose that the variability between stud-
ies may be attributed to the relatively small sample size 
and the subjective nature of assessing haze.41,42
Postoperative pain and epithelial healing time are 
two important factors that influence patient preference 
for a specific procedure. In 2002, Litwak et al.43 report-
ed that LASEK induced more pain than standard PRK. 
However, in our study, the results showed that there 
was no statistically significant difference between PRK 
and LASEK, and the SUCRA ranking showed that PRK 
was more likely to cause pain than LASEK at 1 day 
postoperatively. These differences may be attributable 
to the devitalized flap in LASEK, or it may be the result 
of the release of chemical factors such as prostaglan-
din, histamine, and substance P by corneal tissue.44 
Interestingly, our study found that epi-LASIK resulted 
in more pronounced pain compared to PRK and T-PRK 
at day 3 postoperatively. This might be due to delayed 
epithelial wound healing; Hondur et al.45 reported 
slightly longer epithelial healing time with epi-LASIK 
compared to LASEK.
However, in relation to epithelial healing time, our 
statistical results indicate that heterogeneity is too high 
to draw reliable conclusions. Differing postoperative 
topical drug regimens and the variable use of bandage 
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contact lenses may influence postoperative epithelial 
healing time and could have contributed to this high 
heterogeneity.
In terms of our study limitations, the difference 
between the internal characteristics of research and 
studies based on the small sample sizes can be the key 
factors that influence both heterogeneity in direct com-
parisons and transitivity in indirect comparison.46,47 
For our study, although there are some differences in 
characteristics among the included studies (eg, the race 
of the study population, the choice of laser device, and 
the type or frequency of postoperative medication), 
factors that may have a potential impact on results 
were reasonably consistent (eg, mean dioptric correc-
tion [range: -6.32 to -2.04 D] and mean age [range: 23 
to 35.7 years]). There were only two trials involving 
T-PRK, and with such paucity of data we should be 
cautious with the interpretation of the results involv-
ing T-PRK. We chose the follow-up time point closest 
to 6 months postoperatively to analyze outcomes for 
some studies because of the lack of data after 6 months 
postoperatively. 
It is important to note that our findings are only ap-
plicable to the treatment of myopia without the use of 
MMC. Additional evaluation of the comparative safety 
and effectiveness of corneal surface laser refractive 
surgery with and without MMC is warranted.
Although a range of outcomes was assessed in this 
study, higher order aberrations, contrast sensitiv-
ity, and patient-reported outcomes such as subjective 
quality of vision48,49 were not included due to a lack 
of data in the form of RCTs. This meta-analysis was 
also specifically designed to compare different corneal 
surface ablation techniques rather than excimer laser 
ablation profiles.
This network meta-analysis demonstrates that the 
four major corneal surface laser refractive surgeries for 
the correction of myopia are comparable in efficacy, 
predictability, safety, postoperative haze, and comfort, 
with the exception of pain score on day 3. Epi-LASIK 
was significantly more painful compared to PRK and 
T-PRK on postoperative day 3.
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Figure A. Study selection process. RCT = randomized controlled trial
Figure B. Network of direct comparison for the corneal refractive surgery 
of myopia. Each node represents one treatment. The size of the node is 
proportional to the number of participants randomized to that treatment. 
The edges represent direct comparisons, and the width of the edge is 
proportional to the number of trials. epi-LASIK = epithelial laser in situ 
keratomileusis; LASEK = laser epithelial keratomileusis; PRK = photore-
fractive keratectomy; T-PRK = transepithelial photorefractive keratectomy
Figure C. Summary comparison for postoperative efficacy, predictability, and safety of all treatments derived from the network 
meta-analysis. epi-LASIK = epithelial laser in situ keratomileusis; LASEK = laser epithelial keratectomy; PRK = photorefractive 
keratectomy; T-PRK = transepithelial photorefractive keratectomy
Figure D. Summary comparisons for postoperative haze of all treatments derived from the network meta-analysis. epi-LASIK = 
epithelial laser in situ keratomileusis; LASEK = laser epithelial keratectomy; PRK = photorefractive keratectomy; T-PRK = tran-
sepithelial photorefractive keratectomy
Figure E. Summary comparison for postoperative pain scores and epithelial healing time of all treatments derived from the net-
work meta-analysis. epi-LASIK = epithelial laser in situ keratomileusis; LASEK = laser epithelial keratectomy; PRK = photorefrac-






("Keratectomy, Subepithelial, Laser-Assisted"[Mesh] OR Laser-Assisted Subepithelial Keratectomy OR Laser Subepithelial Keratomileusis OR Laser-Assisted 
Subepithelial Keratomileusis OR LASEK OR epipolis laser in situ keratomileusis OR Epipolis laser in situ keratomileusis OR Epi-LASIK OR "Photorefractive 
Keratectomy"[Mesh] OR Photorefractive Keratectomy OR PRK OR TransPRK OR transepithelial PRK OR transepithelial photorefractive keratectomy OR 
refractive surgery OR laser surgery) AND (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR clinical 
trials as topic [mesh: noexp] OR randomly [tiab] OR trial [ti]) NOT (animals [mh] NOT humans [mh]) AND ((short OR near*) AND sight* OR myop* OR 
myopia[MeSH]) AND (pain [MeSH] OR pain* OR haze OR heal OR healing) 
--------------------------------------- 
Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Wiley) 
#1 MeSH descriptor: [Myopia] explode all trees  
#2 (short OR near*) next sight* 
#3 myop*  
#4 (#1 OR #2 OR #3) 
#5 MeSH descriptor: [Keratectomy, Subepithelial, Laser-Assisted] explode all trees 
#6 Laser-Assisted Subepithelial Keratectomy OR Laser Subepithelial Keratomileusis OR Laser-Assisted Subepithelial Keratomileusis OR LASEK 
#7 epipolis laser in situ keratomileusis OR Epipolis laser in situ keratomileusis OR Epi-LASIK  
#8 MeSH descriptor: [Photorefractive Keratectomy] explode all trees 
#9 Photorefractive Keratectomy OR PRK OR TransPRK OR transepithelial PRK OR transepithelial photorefractive keratectomy OR refractive surgery OR laser 
surgery 
#10 (#5 OR #6 OR #7 OR #8 OR #9) 
#11 (#4 AND #10) 





#16 (#12 OR #13 OR #14 OR #15) 





3. (short or near*) near/3 sight* 
4. OR/1-3 
5. 'laser epithelial keratomileusis'/exp 
6. 'keratomileusis'/exp 
7. 'photorefractive keratectomy'/exp 
8. 'refractive surgery'/exp 
9. 'laser assisted' AND subepithelial AND keratectomy 
10. laser AND subepithelial AND keratomileusis 
11. 'laser assisted' AND subepithelial AND keratomileusis 
12. lasek 
13. epipolis AND laser AND in AND situ AND keratomileusis or AND lasik 
14. epipolis AND laser AND in AND situ AND keratomileusis 
15. 'epi lasik' 
16. photorefractive AND keratectomy 
17. prk 
18. 'trans prk' 
19. refractive AND surgery 









28. 4 AND 21 AND 26 AND 27 
29. pain/exp 




34. 28 AND 33 
--------------------------------------- 
ClinicalTrials.gov search strategy 
(PRK OR LASIK OR LASEK OR EPI-LASIK OR SBK OR FLEX OR SMILE) AND Myopia 
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T-PRK vs 
LASEK 
/ / 4.31 (0.28,75.55) Low 4.31 (0.28,75.55) Low 
T-PRK vs 
Epi-LASIK 
/ / 0.85 (0.03,26.38) Low 0.85 (0.03,26.38) Low 
LASEK vs 
Epi-LASIK 





























1.25 (-0.06, 2.56) Low -0.97 (-2.82, 0.81) Low 0.49 (-0.99, 1.82) Low 
PRK vs 
LASEK 
-0.22 (-1.27, 0.78) Moderate -2.44 (-4.51, -0.46) Low -0.69 (-1.79, 0.50) Moderate 
PRK vs 
Epi-LASIK 
-0.01 (-1.76, 1.66) Moderate / / 0.06 (-2.43,2.49) Moderate 
T-PRK vs 
LASEK 
-1.20 (-2.72, 0.29) Low 1.04 (-0.62, 2.65) Low -0.20 (-1.69, 1.22) Low 
T-PRK vs 
Epi-LASIK 
/ / 0.54 (-2.34,3.27) Low 0.54 (-2.34,3.27) Low 
LASEK vs 
Epi-LASIK 


























0.49 (-1.27, 2.27) Moderate 0.82 (-1.71, 3.20) Low 0.51 (-0.51, 1.67) Moderate 
PRK vs 
LASEK 
0.07 (-1.08, 1.39) Moderate 0.37 (-2.44, 3.14) Low 0.12 (-0.69, 1.04) Moderate 
PRK vs 
Epi-LASIK 
-2.16 (-3.55, -0.77) High / / 2.17 (0.19,4.01) High 
T-PRK vs 
LASEK 
0.81 (-1.22, 3.00) Low 0.59 (-1.54, 2.84) Moderate 0.64 (-0.39, 1.88) High 
T-PRK vs 
Epi-LASIK 
/ / 2.69 (0.51,4.84) Moderate 2.69 (0.51,4.84) Moderate 
LASEK vs 
Epi-LASIK 
/ / 2.03 (-0.16,4.03) Moderate 2.03 (-0.16,4.03) Moderate 
Epithelial healing time 
Comparison 
 























1.57 (1.39, 1.75) Moderate / / 1.57 (-0.04,3.15) Moderate 
PRK vs 
LASEK 
-0.03 (-0.67, 0.58) Moderate -0.33 (-2.18, 1.56) Low -0.01 (-0.56, 0.56) Moderate 
PRK vs 
Epi-LASIK 
-0.12 (-1.47, 1.24) Low 0.17 (-1.37, 1.58) Low 0.08 (-0.81, 0.99) Low 
T-PRK vs 
LASEK 
/ / 1.56 (-0.14,3.23) Moderate 1.56 (-0.14,3.23) Moderate 
T-PRK vs 
Epi-LASIK 
/ / 1.6 5(-0.21,3.46) Low 1.65 (-0.21,3.46) Low 
LASEK vs 
Epi-LASIK 
-0.15 (-1.13, 0.90) Low 0.29 (-1.18, 1.64) Low -0.09 (-0.96, 0.76) Low 
  
Table D 
High Heterogeneity Among Some Comparisons (Forest Plots) 
4-1 LASEK vs PRK for postoperative Haze scores 
 
 



















5-1 Efficacy (UCVA of 20/20 or better) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.16 0.15 0.36 0.32 
LASEK 0.43 0.41 0.14 0.02 
PRK 0.14 0.36 0.38 0.12 
T-PRK 0.27 0.08 0.11 0.54 
 
5-2 Predictability (Refractive SE within ±0.50 D of the target) 
Drug Rank 1 Rank 2 Rank 3 
Epi-LASIK 0.34 0.2 0.46 
LASEK 0.54 0.36 0.1 
PRK 0.12 0.44 0.44 
 
5-3 Safety (Losing two or more lines of BSCVA)  
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.32 0.14 0.17 0.38 
LASEK 0.16 0.24 0.37 0.22 
PRK 0.19 0.45 0.29 0.08 
T-PRK 0.33 0.17 0.18 0.32 
 
 
5-4 Postoperative haze scores 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.12 0.17 0.21 0.51 
LASEK 0.02 0.32 0.49 0.17 
PRK 0.65 0.26 0.07 0.02 
T-PRK 0.22 0.25 0.23 0.3 
 
5-5 Postoperative haze grade 0.5 or higher 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.17 0.13 0.37 0.33 
LASEK 0.49 0.35 0.13 0.02 
PRK 0.27 0.46 0.25 0.02 
T-PRK 0.07 0.06 0.25 0.62 
 
  
5-6 Postoperative Haze grade 1.0 or higher 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.05 0.07 0.36 0.52 
LASEK 0.61 0.27 0.10 0.01 
PRK 0.24 0.57 0.17 0.02 
T-PRK 0.10 0.08 0.37 0.45 
 
5-7 Postoperative pain scores on day 1 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.15 0.13 0.24 
LASEK 0.05 0.14 0.35 0.45 
PRK 0.34 0.48 0.15 0.03 
T-PRK 0.13 0.22 0.37 0.28 
 
5-8 Postoperative pain scores on day 3 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.96 0.02 0.01 0.01 
LASEK 0.02 0.62 0.3 0.05 
PRK 0.01 0.33 0.61 0.06 
T-PRK 0.01 0.04 0.08 0.88 
 
5-9 Postoperative epithelial healing time 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.2 0.3 0.03 
LASEK 0.23 0.42 0.34 0.02 
PRK 0.27 0.38 0.34 0.01 





Node-splitting Analysis of Inconsistency 
Name Outcome Direct estimate (95% Cl) 
Indirect estimate (95% 
Cl) 
Overall (95% Cl) 
P-value for 
inconsistency 
LASEK vs Epi-LASIK Efficacy 0.37 (-0.59, 1.30) 0.38 (-0.76, 1.60) 0.29 (-0.56, 1.16) 0.99 
Epi-LASIK vs PRK Efficacy -0.15 (-1.19, 0.68) 0.51 (-2.07, 2.49) -0.15 (-1.01, 0.69) 0.62 
LASEK vs PRK Efficacy 0.15 (-0.27, 0.60) -0.33 (-2.97, 2.17) 0.15 (-0.28, 0.58) 0.71 
LASEK vs Epi-LASIK Predictability 0.21 (-0.88, 1.27) -0.01 (-1.22, 1.20) 0.16 (-0.75, 0.98) 0.75 
Epi-LASIK vs PRK Predictability 0.05 (-0.92, 1.03) 0.24 (-2.74, 2.32) 0.03 (-0.84, 0.92) 0.86 
LASEK vs PRK Predictability 0.19 (-0.29, 0.61) 0.12 (-2.50, 2.58) 0.19 (-0.26, 0.61) 0.96 
LASEK vs Epi-LASIK 
Haze grade 
0.5 or higher -0.02 (-1.68, 1.75) 1.22 (-0.67, 3.34) 0.51 (-0.76, 1.83) 0.32 
Epi-LASIK vs PRK 
Haze grade 
0.5 or higher -1.04 (-3.07, 0.83) 0.17 (-1.66, 1.98) -0.40 (-1.73, 0.81) 0.34 
LASEK vs PRK 
Haze grade 
0.5 or higher 0.16 (-0.49, 0.85) -1.15 (-3.67, 1.36) 0.10 (-0.54, 0.75) 0.33 
LASEK vs Epi-LASIK 
Haze grade 
1.0 or higher -0.06 (-3.91, 3.74) 2.87 (-0.18, 7.00) 1.60 (-0.71, 4.13) 0.22 
Epi-LASIK vs PRK 
Haze grade 
1.0 or higher -2.31 (-6.26, 0.50) 0.50 (-3.48, 4.49) -1.29 (-3.76, 0.94) 0.23 
LASEK vs PRK 
Haze grade 
1.0 or higher 0.49 (-0.77, 1.82) -2.38 (-7.26, 2.62) 0.29 (-0.92, 1.57) 0.23 
LASEK vs PRK 
Pain scores 
on day 1 -0.22 (-1.27, 0.78) -2.44 (-4.51, -0.46) -0.69 (-1.79, 0.50) 0.05 
LASEK vs T-PRK 
Pain scores 
on day 1r -1.20 (-2.72, 0.29) 1.04 (-0.62, 2.65) -0.20 (-1.69, 1.22) 0.05 
  
PRK vs T-PRK 
Pain scores 
on day 1 1.25 (-0.06, 2.56) -0.97 (-2.82, 0.81) 0.49 (-0.99, 1.82) 0.05 
LASEK vs PRK 
Pain scores 
on day 3 0.07 (-1.08, 1.39) 0.37 (-2.44, 3.14) 0.12 (-0.69, 1.04) 0.79 
LASEK vs T-PRK 
Pain scores 
on day 3 0.81 (-1.22, 3.00) 0.59 (-1.54, 2.84) 0.64 (-0.39, 1.88) 0.85 
PRK vs T-PRK 
Pain scores 
on day 3 0.49 (-1.27, 2.27) 0.82 (-1.71, 3.20) 0.51 (-0.51, 1.67) 0.74 
LASEK vs Epi-LASIK 
epithelial 
healing time -0.15 (-1.13, 0.90) 0.29 (-1.18, 1.64) -0.09 (-0.96, 0.76) 0.60 
Epi-LASIK vs PRK 
epithelial 
healing time -0.12 (-1.47, 1.24) 0.17 (-1.37, 1.58) 0.08 (-0.81, 0.99) 0.76 
LASEK vs PRK 
epithelial 
healing time -0.03 (-0.67, 0.58) -0.33 (-2.18, 1.56) -0.01 (-0.56, 0.56) 0.74 
  
Table G 
Sensitivity Analyses Using a Leave-One-Out Procedure in Which Each Trial Is Left Out, One at a Time 
 
7-1 Direct comparison between PRK and LASEK for postoperative Haze scores (removed Autrata 2003) 
 
 
7-2 Comparison for postoperative haze scores of all treatments derived from 
network meta-analysis (removed Autrata 2003) 
Epi-LASIK 0.08 (-0.14, 0.30) 0.18 (-0.08, 0.44) 0.09 (-0.22, 0.41) 
-0.08 (-0.30, 0.14) LASEK 0.10 (-0.03, 0.23) 0.01 (-0.22, 0.23) 
-0.18 (-0.44, 0.08) -0.10 (-0.23, 0.03) PRK -0.09 (-0.35, 0.17) 
-0.09 (-0.41, 0.22) -0.01 (-0.23, 0.22) 0.09 (-0.17, 0.35) T-PRK 
Mean difference (95% CrI) 
  
 
7-3 Ranking probabilities of postoperative haze scores (removed 
Autrata 2003) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.05 0.10 0.18 0.67 
LASEK 0.02 0.37 0.51 0.10 
PRK 0.73 0.21 0.04 0.01 
T-PRK 0.21 0.31 0.27 0.21 
 
7-4 SUCRA value of postoperative haze scores 
(removed Autrata 2003) 








7-5 Direct comparison between PRK and LASEK for postoperative Haze scores (removed Ghanem 2008) 
 
 
7-6 Comparison for postoperative haze scores of all treatments derived from network 
meta-analysis (removed Ghanem 2008) 
Epi-LASIK 0.08 (-0.44, 0.62) 0.33 (-0.28, 0.95) 0.09 (-0.66, 0.83) 
-0.08 (-0.62, 0.44) LASEK 0.25 (-0.06, 0.57) 0.01 (-0.52, 0.54) 
-0.33 (-0.95, 0.28) -0.25 (-0.57, 0.06) PRK -0.25 (-0.84, 0.38) 
-0.09 (-0.83, 0.66) -0.01 (-0.54, 0.52) 0.25 (-0.38, 0.84) T-PRK 




7-7 Ranking probabilities of postoperative haze scores (removed 
Ghanem 2008) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.08 0.18 0.22 0.52 
LASEK 0.01 0.33 0.49 0.17 
PRK 0.76 0.18 0.05 0.01 
T-PRK 0.14 0.31 0.25 0.29 
 
7-8 SUCRA value of postoperative haze scores 
(removed Ghanem 2008) 







7-9 Direct comparison between PRK and LASEK for postoperative Haze scores (removed He 2004) 
 
 
7-10 Comparison for postoperative haze scores of all treatments derived from 
network meta-analysis (removed He 2004) 
Epi-LASIK 0.08 (-0.53, 0.69) 0.28 (-0.41, 0.97) 0.09 (-0.76, 0.94) 
-0.08 (-0.69, 0.53) LASEK 0.20 (-0.14, 0.54) 0.01 (-0.60, 0.60) 
-0.28 (-0.97, 0.41) -0.20 (-0.54, 0.14) PRK -0.19 (-0.89, 0.50) 
-0.09 (-0.94, 0.76) -0.01 (-0.60, 0.60) 0.19 (-0.50, 0.89) T-PRK 




7-11 Ranking probabilities of postoperative haze scores (removed 
He 2004) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.13 0.17 0.21 0.49 
LASEK 0.03 0.33 0.47 0.17 
PRK 0.62 0.26 0.09 0.03 
T-PRK 0.22 0.24 0.23 0.31 
 
7-12 SUCRA value of postoperative haze 
scores (removed He 2004) 







7-13 Direct comparison between PRK and LASEK for postoperative Haze scores (removed Le 2001) 
 
 
7-14 Comparison for postoperative haze scores of all treatments derived from 
network meta-analysis (removed Le 2001) 
Epi-LASIK 0.08 (-0.50, 0.67) 0.28 (-0.40, 0.96) 0.09 (-0.74, 0.94) 
-0.08 (-0.67, 0.50) LASEK 0.20 (-0.15, 0.54) 0.01 (-0.59, 0.61) 
-0.28 (-0.96, 0.40) -0.20 (-0.54, 0.15) PRK -0.19 (-0.88, 0.51) 
-0.09 (-0.94, 0.74) -0.01 (-0.61, 0.59) 0.19 (-0.51, 0.88) T-PRK 




7-15 Ranking probabilities of postoperative haze scores (removed 
Le 2001) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.13 0.17 0.21 0.49 
LASEK 0.03 0.33 0.47 0.17 
PRK 0.62 0.26 0.09 0.04 
T-PRK 0.22 0.24 0.23 0.31 
 
7-16 SUCRA value of postoperative haze 
scores (removed Le 2001) 







7-17 Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis (removed Wang 2014) 
Epi-LASIK -0.25 (-2.57, 2.01) -0.03 (-2.12, 2.03) -1.25 (-3.68, 1.12) 
0.25 (-2.01, 2.57) LASEK 0.23 (-0.78, 1.25) -0.99 (-2.62, 0.67) 
0.03 (-2.03, 2.12) -0.23 (-1.25, 0.78) PRK -1.23 (-2.54, 0.10) 
1.25 (-1.12, 3.68) 0.99 (-0.67, 2.62) 1.23 (-0.10, 2.54) T-PRK 
Mean difference (95% CrI) 
 
  
7-18 Ranking probabilities of postoperative pain scores on day 1 
(removed Wang 2014) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.14 0.27 0.12 
LASEK 0.18 0.33 0.43 0.06 
PRK 0.33 0.50 0.16 0.01 
T-PRK 0.01 0.03 0.14 0.82 
 
7-19 SUCRA value of postoperative pain scores 
on day 1 (removed Wang 2014) 






7-20 Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis (removed Celik 2014) 
Epi-LASIK -0.27 (-2.58, 2.02) -0.03 (-2.14, 1.99) 0.98 (-1.81, 3.63) 
0.27 (-2.02, 2.58) LASEK 0.23 (-0.77, 1.24) 1.24 (-0.23, 2.73) 
0.03 (-1.99, 2.14) -0.23 (-1.24, 0.77) PRK 1.03 (-0.77, 2.80) 
-0.98 (-3.63, 1.81) -1.24 (-2.73, 0.23) -1.03 (-2.80, 0.77) T-PRK 




7-21 Ranking probabilities of postoperative pain scores on day 1 
(removed Celik 2014) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.20 0.29 0.14 0.37 
LASEK 0.01 0.19 0.34 0.46 
PRK 0.05 0.35 0.46 0.15 
T-PRK 0.74 0.18 0.06 0.02 
 
7-22 SUCRA value of postoperative pain scores 
on day 1 (removed Celik 2014) 






7-23 Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis (removed Pirouzian 2004) 
Epi-LASIK -0.92 (-3.64, 1.91) -0.06 (-2.52, 2.39) -0.62 (-3.45, 2.29) 
0.92 (-1.91, 3.64) LASEK 0.86 (-0.52, 2.13) 0.29 (-1.22, 1.83) 
0.06 (-2.39, 2.52) -0.86 (-2.13, 0.52) PRK -0.57 (-1.99, 0.98) 
0.62 (-2.29, 3.45) -0.29 (-1.83, 1.22) 0.57 (-0.98, 1.99) T-PRK 




7-24 Ranking probabilities of postoperative pain scores on day 1 
(removed Pirouzian 2004) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.48 0.17 0.13 0.21 
LASEK 0.04 0.12 0.34 0.50 
PRK 0.35 0.48 0.14 0.03 
T-PRK 0.12 0.22 0.40 0.26 
 
7-25 SUCRA value of postoperative pain scores 
on day 1 (removed Pirouzian 2004) 






7-26 Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis (removed Saleh 2003) 
Epi-LASIK -0.79 (-3.57, 1.99) -0.04 (-2.48, 2.39) -0.53 (-3.33, 2.35) 
0.79 (-1.99, 3.57) LASEK 0.75 (-0.65, 2.00) 0.25 (-1.29, 1.81) 
0.04 (-2.39, 2.48) -0.75 (-2.00, 0.65) PRK -0.51 (-1.91, 1.10) 
0.53 (-2.35, 3.33) -0.25 (-1.81, 1.29) 0.51 (-1.10, 1.91) T-PRK 




7-27 Ranking probabilities of postoperative pain scores on day 1 
(removed Saleh 2003) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.47 0.17 0.13 0.23 
LASEK 0.05 0.14 0.33 0.47 
PRK 0.34 0.47 0.16 0.03 
T-PRK 0.14 0.22 0.37 0.26 
 
7-28 SUCRA value of postoperative pain scores 
on day 1 (removed Saleh 2003) 






7-29 Comparison for postoperative pain scores on day 1 of all treatments derived 
from network meta-analysis (removed Sia 2004) 
Epi-LASIK -1.24 (-3.72, 1.76) -0.10 (-2.40, 2.30) -0.85 (-3.33, 2.17) 
1.24 (-1.76, 3.72) LASEK 1.13 (-0.50, 2.41) 0.47 (-1.09, 1.87) 
0.10 (-2.30, 2.40) -1.13 (-2.41, 0.50) PRK -0.75 (-1.96, 0.90) 
0.85 (-2.17, 3.33) -0.47 (-1.87, 1.09) 0.75 (-0.90, 1.96) T-PRK 




7-30 Ranking probabilities of postoperative pain scores on day 1 
(removed Sia 2004) 
Drug Rank 1 Rank 2 Rank 3 Rank 4 
Epi-LASIK 0.53 0.19 0.12 0.17 
LASEK 0.03 0.09 0.27 0.61 
PRK 0.34 0.53 0.10 0.02 
T-PRK 0.10 0.20 0.51 0.20 
 
7-31 SUCRA value of postoperative pain scores 
on day 1 (removed Sia 2004) 








Comparison-Adjusted Funnel Plots 
8-1 Funnel plot to confirm the risk of publications bias for the ten included studies which reported postoperative efficacy 
 
 






8-3 Funnel plot to confirm the risk of publications bias for the six included studies which reported postoperative safety 
 
 








8-5 Funnel plot to confirm the risk of publications bias for the seven included studies which reported postoperative haze grade 0.5 or higher 
 
 








8-7 Funnel plot to confirm the risk of publications bias for the six included studies which reported postoperative pain scores at day 1 
 
 




8-9 Funnel plot to confirm the risk of publications bias for the twelve included studies which reported postoperative epithelial healing time 
 
